跳至主要内容
临床试验/NCT01814774
NCT01814774已完成不适用

A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm

Allergan0 个研究点目标入组 48 人开始时间: 2013年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Allergan
入组人数
48
主要终点
Dose of Botulinum Toxin Used to Treat Blepharospasm

研究概览

简要总结

This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
  • treatment with Xeomin® and BOTOX® for at least 1 year each

排除标准

  • having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
  • previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm

结局指标

主要结局

Dose of Botulinum Toxin Used to Treat Blepharospasm

时间窗: 2 Years

The average dose of botulinum toxin received per patient per year was calculated.

Dose of Botulinum Toxin Used to Treat Cervical Dystonia

时间窗: 2 Years

The average dose of botulinum toxin received per patient per year was calculated.

次要结局

  • Number of Participants With Adverse Events(2 Years)
  • Botulinum Toxin Inter-injection Interval(2 Years)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验